D. E. Shaw & Co., Inc. Gossamer Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.8 - $1.51 $68,800 - $129,861	86,001 Added 16.97%	592,889 $699,000
Q4 2023 Feb 14, 2024	BUY	$0.48 - $1.08 $113,077 - $254,424	235,578 Added 86.83%	506,888 $461,000
Q3 2023 Nov 14, 2023	SELL	$0.78 - $1.82 $82,304 - $192,044	-105,519 Reduced 28.0%	271,310 $225,000
Q2 2023 Aug 14, 2023	BUY	$0.98 - $1.53 $235,840 - $368,200	240,654 Added 176.72%	376,829 $452,000
Q1 2023 May 15, 2023	SELL	$0.96 - $2.92 $172,272 - $523,994	-179,450 Reduced 56.86%	136,175 $171,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $12.87 $51,968 - $384,388	29,867 Added 10.45%	315,625 $684,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $1.79 Million - $3.69 Million	248,010 Added 657.01%	285,758 $3.42 Million
Q2 2022 Aug 15, 2022	SELL	$5.97 - $9.97 $30,841 - $51,505	-5,166 Reduced 12.04%	37,748 $316,000
Q1 2022 May 16, 2022	BUY	$8.44 - $12.49 $362,194 - $535,995	42,914 New	42,914 $372,000

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $78.9M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.